Impel Pharmaceuticals

What Impel Pharmaceuticals does

Impel Pharmaceuticals (formerly Impel NeuroPharma; legal entity Impel Pharmaceuticals LLC) is a commercial-stage, specialty pharmaceutical company headquartered in Seattle, Washington, with 51-100 employees. The company develops intranasal drug treatments for central nervous system disorders characterized by high unmet medical need, anchored by Trudhesa (dihydroergotamine mesylate) nasal spray 0.725 mg per spray, which is FDA-approved for the acute treatment of migraine with or without aura in adults. The company's principal proprietary asset is its Precision Olfactory Delivery (POD) platform, a device-and-formulation technology engineered to deposit therapeutics consistently in the upper nasal space — a region surrounded by rich vasculature that enables injection-like absorption kinetics — addressing what the company describes as a historical inability of other technologies to reach that target predictably.

The business model is a prescription specialty pharma model: Trudhesa is sold through standard pharmaceutical wholesale distribution channels into retail pharmacies, with revenue generated by prescription volume at negotiated rates with payors and PBMs. Go-to-market is enterprise field sales targeting neurologists, headache specialists, and primary care prescribers, supplemented by a Trudhesa Direct support program and a digital presence (corporate website, Twitter @ImpelPharma, LinkedIn "Impel Pharma"). Trudhesa carries a portfolio of registered trademarks (Trudhesa, Trudhesa Direct) alongside the IMPEL and POD marks.

Impel raised capital through a multi-stage trajectory: early seed and Series A activity with Alliance of Angels, a 2016 round from 5AM Ventures / venBio / Vivo, a 2018 Series C led by Kohlberg Kravis Roberts and Norwest ($67.5M), an IPO-era $50M debt facility from Oxford Finance and Silicon Valley Bank (2021-07) followed by a $45M public offering at a $135M pre-money valuation (2021-09), and a $100M financing from Oaktree Capital Management (2022-03) structured as $50M royalty agreement plus $50M senior secured debt. The company was listed on NASDAQ under ticker IMPL and is now reported as delisted; operating status is reported as active with the company's stated intent to license the POD platform for additional small- and large-molecule programs.

Name

Impel Pharmaceuticals

Legal name

Impel Pharmaceuticals LLC

Website

https://impelnp.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Impel Pharmaceuticals is a Seattle-based, commercial-stage specialty pharmaceutical company that develops intranasal drug treatments for central nervous system disorders, anchored by FDA-approved Trudhesa (dihydroergotamine mesylate) nasal spray for acute migraine in adults using its proprietary POD delivery technology.

Ownership category

akta.pro rank

Product category

Migraine Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Intranasal drug delivery
• Migraine therapeutics
• Nasal spray medication
• CNS disorder treatments
• Prescription pharmaceuticals

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Trudhesa Product Sales: Revenue generated from the sale of Trudhesa (dihydroergotamine mesylate) nasal spray, an FDA-approved acute treatment for migraine with or without aura in adults. As a commercial-stage pharmaceutical company, revenue comes from prescription drug sales through pharmaceutical distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Impel Pharmaceuticals is a commercial-stage pharmaceutical company that develops and markets Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray), an FDA-approved acute treatment for migraine with or without aura in adults. The product is powered by the company's proprietary Precision Olfactory Delivery (POD) technology, which targets the upper nasal space for injection-like drug absorption, enabling more rapid and consistent bioavailability than traditional nasal sprays.

Product overview

Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for disorders with high unmet medical needs. The company's portfolio centers on Trudhesa (dihydroergotamine mesylate) nasal spray, an FDA-approved acute migraine treatment, which is powered by the proprietary POD (Precision Olfactory Delivery) technology platform. The POD technology enables targeted upper nasal space delivery to achieve injection-like absorption kinetics.

Differentiator

Problem solved

Functional benefit

Brands

• POD Technology: Proprietary Precision Olfactory Delivery technology enabling upper nasal space drug delivery for injection-like absorption
• Trudhesa

Products and services

• Trudhesa (dihydroergotamine mesylate) nasal spray FDA-approved nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults, using the proprietary POD technology for optimized upper nasal space delivery.
• POD (Precision Olfactory Delivery) Technology Platform Proprietary drug delivery platform designed to target the upper nasal space, which is surrounded by rich vasculature enabling injection-like absorption for more rapid and consistent bioavailability and clinical response. The company is open to partnerships, collaborations and licensing opportunities to explore the therapeutic potential of the technology.

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Biohaven Pharmaceuticals: Developed and commercialized Nurtec ODT, a leading oral CGRP antagonist for acute and preventive migraine treatment. Direct therapeutic-area competitor to Trudhesa in the acute migraine market with overlapping prescriber base among neurologists and headache specialists.
• Satsuma Pharmaceuticals: Developed an intranasal dihydroergotamine formulation (STS101) for acute migraine using a proprietary nasal delivery device, conceptually the closest direct competitor to Trudhesa in mechanism, indication, and delivery route.

Broad incumbents

• Allergan (now AbbVie): Markets Ubrelvy (ubrogepant), an oral CGRP antagonist for acute migraine, as part of a broad neurology and aesthetics portfolio. Competes with Trudhesa for acute migraine prescriptions through far larger sales and payer-access infrastructure.
• Eli Lilly: Markets Emgality (galcanezumab), an injectable CGRP antibody, and the 5-HT1F agonist Reyvow (lasmiditan) for acute migraine. Competes with Trudhesa across both preventive and acute migraine settings via a global commercial organization.
• Teva Pharmaceutical Industries: Markets Ajovy (fremanezumab), an injectable CGRP antibody for migraine prevention. As a major generics and specialty manufacturer, Teva is a broad incumbent competitor to Impel in the migraine space and also a potential acquirer of neurology assets.
• Amgen: Co-markets Aimovig (erenumab) with Novartis, the first-to-market injectable CGRP antibody for migraine prevention. Represents a large-cap incumbent competing for migraine prescriptions with substantially greater commercial reach than Impel.
• Lundbeck: Markets Vyepti (eptinezumab), an IV-administered CGRP antibody for migraine prevention, following its acquisition of Alder BioPharmaceuticals. A focused CNS player whose migraine franchise overlaps with Trudhesa's specialty neurology channel.

Emerging players

• Zosano Pharma: Developed a microneedle patch intradermal delivery system for migraine and other CNS indications. Comparable to Impel as a small, technology-driven drug-delivery company targeting acute migraine with a proprietary non-oral delivery platform.
• Axsome Therapeutics: Commercial-stage CNS-focused company that launched Auvelity for major depressive disorder and is developing migraine therapies. Comparable as a small, specialty commercial CNS company competing for similar prescriber mindshare in neurology.
• Currax Pharmaceuticals: Specialty pharmaceutical company marketing Onzetra Xsail, an intranasal sumatriptan for acute migraine using a breath-powered nasal delivery device. Closely comparable to Impel as a smaller migraine-focused company with a proprietary nasal delivery product.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/NosetoBrain
• LinkedInlinkedin.com/company/impel-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impel Pharmaceuticals